Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6487
    -0.0013 (-0.20%)
     

  • OIL

    82.60
    -0.21 (-0.25%)
     

  • GOLD

    2,339.30
    +0.90 (+0.04%)
     

  • Bitcoin AUD

    97,307.52
    -4,598.23 (-4.51%)
     

  • CMC Crypto 200

    1,351.99
    -30.58 (-2.21%)
     

  • AUD/EUR

    0.6072
    +0.0002 (+0.03%)
     

  • AUD/NZD

    1.0954
    +0.0012 (+0.11%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,065.40
    +25.02 (+0.31%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,893.05
    -195.65 (-1.08%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Zimmer Biomet's stock falls after pricing secondary offering

Ivan Levingston
Updated

Zimmer Biomet (NYSE: ZBH), a medical device maker based in Indiana, announced Tuesday it was initially pricing its secondary offering of 11.1 million common shares at $115.85.

Shares of the company dropped about 1.5 percent to about $116 a share.

The offering is being underwritten by Goldman Sachs and JPMorgan Chase and is expected to close June 16.

The company recently announced it was purchasing rival medical device maker LDR Holding (NASDAQ: LDRH) for $1 billion, paying a 64 percent premium on the company's closing stock price at the time of the deal. The acquisition of LDR is expected to close in the third quarter. Since January, Zimmer Biomet's stock is up more than 13 percent.

Zimmer Biomet makes reconstructive surgical devices such as hip replacement products.

ZBH in 2016



More From CNBC

  • Top News and Analysis

  • Latest News Video

  • Personal Finance